1. NICE (2017) TA464: bisphosphonates for treating osteoporosis. National Institute for Health and Care Excellence, London
2. Sims I (2017) Many more eligible for bisphosphonates after NICE lowers threshold to 1%. PULSE.
http://www.pulsetoday.co.uk/clinical/more-clinical-areas/musculoskeletal/many-more-eligible-for-bisphosphonates-after-nice-lowers-threshold-to-1/20034787.article
. Accessed 26/07/2017 2017
3. NICE (2008) TA160: alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended). National Institute for Health and Care Excellence, London
4. NICE (2008) TA161: alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Care Excellence, London
5. Kanis JA, McCloskey E, Jonsson B, Cooper A, Strom O, Borgstrom F (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Arch Osteoporos 5:19–48